Union Jobs Report
PILMA news
Request for Information – Commonsense Policy Options to Lower Drug Prices for Patients
August 17, 2026 The Honorable Ron Wyden Ranking Member, Senate Committee on Finance 219 Dirksen Senate Office Building Washington, DC 20510 Re: Request for Information – Commonsense Policy Options to Lower Drug Prices for Patients Dear Ranking Member Wyden and Members of the Senate Finance Committee Minority, On behalf of
CMS-4215-P – Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
August 17, 2026 The Honorable Mehmet Oz Administrator, Centers for Medicare and Medicaid Services U.S. Department of Health and Human Services Attn: CMS-4215-P, P.O. Box 8013, Baltimore, MD 21244 Re: CMS-4215-P – Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Dear Administrator Oz, On behalf of the
Section 301 Investigation of Germany’s Pharmaceutical Pricing Policies — Docket ID USTR-2026-0463
August 9, 2026 Ambassador Jamieson GreerUnited States Trade Representative600 17th Street NWWashington, DC 20508Re: Section 301 Investigation of Germany’s Pharmaceutical Pricing Policies — DocketID USTR-2026-0463Dear Ambassador Greer,I write today to voice my support of the United States Trade Representative’s decision toinitiate a Section 301 investigation into Germany’s pharmaceutical pricing policies.
PILMA Letter to HELP Committee: MAPIA
June 15, 2026 Dear Members of the Senate Committee on Health, Education, Labor and Pensions: The Pharmaceutical Industry Labor-Management Association (PILMA), a coalition uniting the biopharmaceutical industry and America’s building trades unions around a shared commitment to medical innovation and high-quality union jobs, strongly opposes the Medication Affordability and Patent